AstraZeneca reports that positive results from a Phase III trial showed that Imfinzi (durvalumab) significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with limited-stage small-cell lung cancer (LS-SCLC) after standard chemoradiotherapy.

Imfinzi reduced the risk of death by 27%, and median survival was 55.9 months versus 33.4 months for placebo. What's more, 57% of patients treated with Imfinzi were alive after three years, compared with 48% with placebo.

The significant improvement in overall survival observed with Imfinzi after concurrent chemoradiotherapy is transformative in the treatment of limited-stage small-cell lung cancer", said Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca.


Copyright (c) 2024 CercleFinance.com. All rights reserved.